OncoMatch/Clinical Trials/NCT03786692
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Is NCT03786692 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Arm A and Arm B for non-small cell carcinoma of lung, tnm stage 4.
Treatment: Arm A · Arm B — While cigarette smoking remains the primary cause of most lung cancer cases, lung carcinoma in never smokers account for nearly 20 percent of cases. Never smokers with lung cancer typically present with different molecular profiles from that of smokers, which results in prognostic and therapeutic implications. Molecular changes in NSCLC that have therapeutic significance include mutations in the epidermal growth factor receptor (EGFR) and rearrangements in the anaplastic lymphoma kinase (ALK) gene. These driver mutations typically are present in lung tumors found in never or light smokers. The addition of bevacizumab to carboplatin and paclitaxel in first-line treatment of non-squamous NSCLC showed improved survival compared to carboplatin and paclitaxel alone, 12.3 vs. 10.3 months respectively. Results from the POINTBREAK trial demonstrated that carboplatin + pemetrexed + bevacizumab is an alternative option to carboplatin + paclitaxel + bevacizumab, with comparable survival but less toxicity. In recent years, immunotherapy has emerged as a form of treatment that can lead to robust responses in a subset of patients. The PD-1 inhibitor nivolumab and the PD-L1 inhibitor atezolizumab have shown prolonged survival in comparison to docetaxel in patients who previously progressed with chemotherapy, irrespective of PD-L1 expression. Thus, this study combines immunotherapeutic agent atezolozumab with an ant-angiogenic agent, bevacizumab, and double platinum therapy (carboplatin and pemetrexed).
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: EGFR exon 19 mutation
tumors that harbor an EGFR mutation in exon 19 or exon 21
Required: EGFR exon 21 mutation
tumors that harbor an EGFR mutation in exon 19 or exon 21
Required: EGFR wild-type
never smoker wild-types are defined as patients with tumors without an ALK or ROS1 rearrangement, and are not harboring any EGFR mutation (this includes exons 19 or 21, exon 20, and any other rare EGFR mutations)
Required: ALK wild-type
never smoker wild-types are defined as patients with tumors without an ALK or ROS1 rearrangement
Required: ROS1 wild-type
never smoker wild-types are defined as patients with tumors without an ALK or ROS1 rearrangement
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor
Tumors that harbor an EGFR exon 19 or exon 21 mutation must have received prior treatments with one or more TKIs
Cannot have received: chemotherapy
Exception: prior oral TKIs required for EGFR mutated patients
Must be chemotherapy, anti-VEGF therapy alone, and immunotherapy naive, with the exception of prior oral TKIs which are required for EGFR mutated patients
Cannot have received: anti-VEGF therapy
Exception: prior anti-VEGF therapy in combination with a TKI for advanced stage EGFR-mutated disease may be included
Must be chemotherapy, anti-VEGF therapy alone, and immunotherapy naive, with the exception of prior oral TKIs which are required for EGFR mutated patients. Patients who have received prior anti-VEGF therapy in combination with a TKI for advanced stage EGFR-mutated disease may be included
Cannot have received: immunotherapy
Must be chemotherapy, anti-VEGF therapy alone, and immunotherapy naive
Lab requirements
Blood counts
Absolute neutrophil count > 1,500/mcL; Hemoglobin ≥ 9.0 mg/ml; Platelets > 100,000/mcL
Kidney function
Creatinine OR Creatinine clearance ≤1.5 X ULN, OR > 40 ml/min/1.73 m2 for patients with creatinine levels above institutional normal as per Cockcroft-Gault formula
Liver function
Total bilirubin ≤1.5 X institutional ULN; AST/ALT < 3x ULN, or up to 5x ULN if liver metastases
Must have normal organ and marrow function as defined below. ... Absolute neutrophil count > 1,500/mcL Hemoglobin ≥ 9.0 mg/ml Platelets > 100,000/mcL Total bilirubin ≤1.5 X institutional upper limit of normal (ULN) AST/ALT (SGOT/SGPT) < 3 times institutional normal limits, or up to 5 times institutional normal limits if the patient has liver metastases Creatinine OR Creatinine clearance ≤1.5 X ULN, OR > 40 Ml/min/1.73 m2 for patients with creatinine levels above institutional normal as per Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fox Chase Cancer Center · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify